

<b>General information about company</b>	
Scrip code*	538734
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE016Q01014
Name of company	Ceinsys Tech Ltd
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2024
Date of end of financial year	31-03-2025
Date of board meeting when results were approved	03-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	29-04-2025
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Single segment
Start date and time of board meeting	03-05-2025 13:00
End date and time of board meeting	03-05-2025 16:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	Yes
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	17-01-2025
Indicate Company website link for updated RPT policy of the Company	<a href="https://www.ceinsys.com/wp-content/uploads/2025/02/Policy_on_Related_Party_Transaction.pdf">https://www.ceinsys.com/wp-content/uploads/2025/02/Policy_on_Related_Party_Transaction.pdf</a>
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

Financial Results – Ind-AS			
Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period	01-01-2025	01-04-2024	
Date of end of reporting period	31-03-2025	31-03-2025	
Whether results are audited or unaudited	Audited	Audited	
Nature of report standalone or consolidated	Standalone	Standalone	
<b>Part I</b>	<b>Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.</b>		
<b>1</b>	<b>Income</b>		
	Revenue from operations	13814	39973
	Other income	336	2587
	<b>Total income</b>	<b>14150</b>	<b>42560</b>
<b>2</b>	<b>Expenses</b>		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	1754	3547
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-18	12
(d)	Employee benefit expense	2258	9750
(e)	Finance costs	134	229
(f)	Depreciation, depletion and amortisation expense	161	563
(g)	<b>Other Expenses</b>		
1	Project and other Operating Expenses	5203	12276
2	Other Expenses	1420	5102
	<b>Total other expenses</b>	<b>6623</b>	<b>17378</b>
	<b>Total expenses</b>	<b>10912</b>	<b>31479</b>
<b>3</b>	<b>Total profit before exceptional items and tax</b>	<b>3238</b>	<b>11081</b>
4	Exceptional items	0	0
<b>5</b>	<b>Total profit before tax</b>	<b>3238</b>	<b>11081</b>
<b>6</b>	<b>Tax expense</b>		
7	Current tax	953	3163
8	Deferred tax	-140	-220
<b>9</b>	<b>Total tax expenses</b>	<b>813</b>	<b>2943</b>
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
<b>11</b>	<b>Net Profit Loss for the period from continuing operations</b>	<b>2425</b>	<b>8138</b>
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
<b>14</b>	<b>Net profit (loss) from discontinued operation after tax</b>	<b>0</b>	<b>0</b>
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
<b>16</b>	<b>Total profit (loss) for period</b>	<b>2425</b>	<b>8138</b>
17	<a href="#">Other comprehensive income net of taxes</a>	-24	-36
<b>18</b>	<b>Total Comprehensive Income for the period</b>	<b>2401</b>	<b>8102</b>
<b>19</b>	<b>Total profit or loss, attributable to</b>		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
<b>20</b>	<b>Total Comprehensive income for the period attributable to</b>		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
<b>21</b>	<b>Details of equity share capital</b>		
	Paid-up equity share capital	1744	1744
	Face value of equity share capital	10	10
22	Reserves excluding revaluation reserve	38681	
<b>23</b>	<b>Earnings per share</b>		
<b>i</b>	<b>Earnings per equity share for continuing operations</b>		
	Basic earnings (loss) per share from continuing operations	13.9	48.09
	Diluted earnings (loss) per share from continuing operations	12.45	45.39
<b>ii</b>	<b>Earnings per equity share for discontinued operations</b>		
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
<b>iii</b>	<b>Earnings per equity share (for continuing and discontinued operations)</b>		
	Basic earnings (loss) per share from continuing and discontinued operations	13.9	48.09
	Diluted earnings (loss) per share from continuing and discontinued operations	12.45	45.39
24	Debt equity ratio		Textual Information( 1)
25	Debt service coverage ratio		Textual Information( 2)
26	Interest service coverage ratio		Textual Information( 3)
27	<b>Disclosure of notes on financial results</b>	<b>Textual Information(4)</b>	

**Text Block**

Textual Information(4)	<p>Notes forming to the Standalone Audited Financial Results for the Quarter and Year ended March 31, 2025</p> <p>1. These Standalone audited Financial Results of Ceinsys Tech Limited (the "Company") for the quarter and year ended March 31, 2025 ("the statement") were reviewed by Audit Committee and approved by the Board of Directors at their meeting held on May 03, 2025.</p> <p>2.(i) During the year, the Company has granted:</p> <p>a) 6,50,000 options to an eligible employee of the Company pursuant to the "Ceinsys Employee Stock Incentive Scheme 2024", out of which, the employee has surrendered 2,50,000 options and hence stand cancelled.</p> <p>b) 10,16,970 options to the eligible employees of a foreign subsidiary pursuant to the "Ceinsys Employee Stock Option Plan 2024", out of which 8,16,970 options stands cancelled since an employee resigned. The vesting of remaining 2,00,00 options to an employee are subject to achieving the performance parameters by the geospatial operations in that subsidiary company which will be measured as on July 13, 2025. As per the Management of the Company the probability of achieving this performance parameters are remote and hence no cost is considered for the same as on March 31, 2025.</p> <p>2.(ii) Employee benefits expense for the quarter and Year ended March 31, 2025 includes share-based payment of Rs. 138 Lakhs and Rs. 1,325 Lakhs respectively charged to statement of Profit &amp; Loss.</p> <p>3. During the year, as approved by the shareholders of the Company:</p> <p>(i) The Company allotted 11,01,749 Equity Shares of Face Value of Rs. 10 each at an issue price of Rs. 559.90 per equity share (including a premium of Rs. 549.90 per Equity Share) aggregating to Rs. 6,169 Lakhs on preferential basis.</p> <p>(ii) The Company allotted 30,96,515 Shares Warrants, convertible into equivalent number of equity shares, at an issue price of Rs. 559.90 per share warrant, aggregating to Rs. 17,337 Lakhs, on preferential basis. Against these Shares Warrants 25% of issue price amounting to Rs. 4,334 Lakhs has been received.</p> <p>(iii) As on March 31, 2025, out of the above proceeds, the unutilised amount of Rs. 10,502 Lakhs is either invested in term deposits or lying in the current account with the Bank.</p> <p>4. The Scheme of Amalgamation of Allygrow Technologies Private Limited, Wholly Owned Subsidiary, with the Company ('the Scheme') has been approved by the Honourable National Company Law Tribunal, Mumbai Bench ('the NCLT') vide its order dated April 09, 2025. The Scheme has April 01, 2024 as appointment date. The Scheme has been given effect in the above standalone financial results as per Appendix-C of Ind AS- 103 "Business Combination of entities under Common Control". Accordingly, the figures for the corresponding / previous quarters and previous year have been restated.</p> <p>5. As per Ind AS 108 'Operating Segments', the Company has disclosed the segment information only as part of the consolidated financial results.</p> <p>6. The Standalone Financial Results includes the figures for the quarter ended March 31, 2025 and March 31, 2024, being the balancing figures between audited figures of full financial year and published year to date figures up to the nine months ended December 31, 2024 and December 31, 2023 respectively. The figures for the corresponding previous periods / year have been regrouped / rearranged wherever necessary, to make them comparable.</p>
------------------------	--

Statement of Asset and Liabilities		
Particulars	Year ended (dd-mm-yyyy)	
	Date of start of reporting period	01-04-2024
	Date of end of reporting period	31-03-2025
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
<b>Assets</b>		
<b>1 Non-current assets</b>		
Property, plant and equipment		3745
Capital work-in-progress		80
Investment property		84
Goodwill		1991
Other intangible assets		92
Intangible assets under development		211
Biological assets other than bearer plants		
Investments accounted for using equity method		
<b>Non-current financial assets</b>		
Non-current investments		3366
Trade receivables, non-current		249
Loans, non-current		1575
Other non-current financial assets		772
	<b>Total non-current financial assets</b>	<b>5962</b>
Deferred tax assets (net)		791
Other non-current assets		127
	<b>Total non-current assets</b>	<b>13083</b>
<b>2 Current assets</b>		
Inventories		51
<b>Current financial asset</b>		
Current investments		0
Trade receivables, current		24932
Cash and cash equivalents		150
Bank balance other than cash and cash equivalents		14925
Loans, current		33
Other current financial assets		546
	<b>Total current financial assets</b>	<b>40586</b>
Current tax assets (net)		730
Other current assets		1566
Total current assets		42933
3 Non-current assets classified as held for sale		0
4 Regulatory deferral account debit balances and related deferred tax Assets		0
Total assets		56016
	<b>Total current assets</b>	<b>42933</b>
3 Non-current assets classified as held for sale		0
4 Regulatory deferral account debit balances and related deferred tax Assets		0
	<b>Total assets</b>	<b>56016</b>
<b>Equity and liabilities</b>		
<b>1 Equity</b>		
<b>Equity attributable to owners of parent</b>		
Equity share capital		1744
Other equity		38681
	<b>Total equity attributable to owners of parent</b>	<b>40425</b>
Non controlling interest		
	<b>Total equity</b>	<b>40425</b>
<b>2 Liabilities</b>		
<b>Non-current liabilities</b>		
<b>Non-current financial liabilities</b>		
Borrowings, non-current		79
<b>Trade Payables, non-current</b>		
(A) Total outstanding dues of micro enterprises and small enterprises		
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		
	<b>Total Trade payable</b>	
Other non-current financial liabilities		414
	<b>Total non-current financial liabilities</b>	<b>493</b>
Provisions, non-current		127
Deferred tax liabilities (net)		
Deferred government grants, Non-current		
Other non-current liabilities		
	<b>Total non-current liabilities</b>	<b>620</b>
<b>Current liabilities</b>		
<b>Current financial liabilities</b>		
Borrowings, current		3582
<b>Trade Payables, current</b>		
(A) Total outstanding dues of micro enterprises and small enterprises		572
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		6849
	<b>Total Trade payable</b>	<b>7421</b>
Other current financial liabilities		1597
	<b>Total current financial liabilities</b>	<b>12600</b>
Other current liabilities		419

	Provisions, current	374
	Current tax liabilities (Net)	1578
	Deferred government grants, Current	0
	<b>Total current liabilities</b>	14971
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	<b>Total liabilities</b>	15591
	<b>Total equity and liabilities</b>	56016
	<b>Disclosure of notes on assets and liabilities</b>	<b>Textual Information(1)</b>

Other Comprehensive Income			
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
Other comprehensive income [Abstract]			
1	Amount of items that will not be reclassified to profit and loss		
1	Remeasurements Gain/(Loss) on defined benefit plans	-32.00	-48.00
	Total Amount of items that will not be reclassified to profit and loss	-32.00	-48.00
2	Income tax relating to items that will not be reclassified to profit or loss	-8.00	-12.00
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	-24.00	-36.00

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	11081
2	<b>Adjustments for reconcile profit (loss)</b>	
	Adjustments for finance costs	229
	Adjustments for decrease (increase) in inventories	13
	Adjustments for decrease (increase) in trade receivables, current	-9228
	Adjustments for decrease (increase) in trade receivables, non-current	58
	Adjustments for decrease (increase) in other current assets	7
	Adjustments for decrease (increase) in other non-current assets	-1557
	Adjustments for other financial assets, non-current	0
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	3000
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	-1190
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	563
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	0
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	2
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	1325
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	828
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	<b>Total adjustments for reconcile profit (loss)</b>	<b>-5950</b>
	<b>Net cash flows from (used in) operations</b>	<b>5131</b>
	Dividends received	-1529
	Interest paid	633
	Interest received	0
	Income taxes paid (refund)	807
	Other inflows (outflows) of cash	-60
	<b>Net cash flows from (used in) operating activities</b>	<b>2102</b>
3	<b>Cash flows from used in investing activities</b>	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	6
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	83
	Purchase of property, plant and equipment	1788
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	1529
	Interest received	426
	Income taxes paid (refund)	0

	Other inflows (outflows) of cash	-6941
	<b>Net cash flows from (used in) investing activities</b>	<b>-6697</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	6169
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	3234
	Repayments of borrowings	37
	Payments of lease liabilities	347
	Dividends paid	408
	Interest paid	79
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	-3935
	<b>Net cash flows from (used in) financing activities</b>	<b>4597</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>2</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>2</b>
	Cash and cash equivalents cash flow statement at beginning of period	148
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>150</b>

**Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd an**

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any incurred to corporat
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	
1	Ceinsys Tech Limited	AACCA3193K	Allygram Systems and Technologies Private Limited	AARCA1060A	Joint Venture of entities under Common Control	Sale of goods or services		-				38.82	0	0	
2	Ceinsys Tech Limited	AACCA3193K	ADCC Infocom Private Limited	AAICA7011N	Subsidiary Company	Interest received		-				-4.75	7.81	3.24	
3	Ceinsys Tech Limited	AACCA3193K	Allygram Systems and Technologies Private Limited	AARCA1060A	Joint Venture of entities under Common Control	Sale of goods or services		-				136.25	0	0	
4	Ceinsys Tech Limited	AACCA3193K	ADCC Infocom Private Limited	AAICA7011N	Subsidiary Company	Any other transaction	Rent received	-				0.06	0.28	0.35	
5	Ceinsys Tech Limited	AACCA3193K	Jawaharlal Nehru Medical College	AAATS7321N	Significant influence	Any other transaction	Sale of land	-				82.62	81.79	0	
6	Ceinsys Tech Limited	AACCA3193K	Primus Finance Private Limited	AABCP9361K	Significant influence	Interest paid		-				0.72	0	0	
7	Ceinsys Tech Limited	AACCA3193K	ADCC Infocom Private Limited	AAICA7011N	Subsidiary Company	Any other transaction	Refund of Interest	-				5.05	5.05	0	
8	Ceinsys Tech Limited	AACCA3193K	Mr. Abhay Kimmatkar	AGLPK2456K	Key Management Personnel	Remuneration		-				62.51	0	0	
9	Ceinsys Tech Limited	AACCA3193K	Mr. Rahul Joharapurkar	AAVPJ1100H	Key Management Personnel	Remuneration		-				43.04	0	0	
10	Ceinsys Tech Limited	AACCA3193K	Mr. Samir Sabharwal	AGEPS3223P	Key Management Personnel	Remuneration		-				33.46	0	0	
11	Ceinsys Tech Limited	AACCA3193K	Mr. Hemant Thakare	AAUPT0722A	Key Management Personnel	Remuneration		-				13.24	0	0	
12	Ceinsys Tech Limited	AACCA3193K	Ms. Pooja Karande	ECKPK8392D	Key Management Personnel	Remuneration		-				6.96	0	0	
13	Ceinsys Tech Limited	AACCA3193K	Mr. Prashant Kamat	AAZPK7734N	Key Management Personnel	Remuneration		-				150.28	0	0	
14	Ceinsys Tech Limited	AACCA3193K	Mr. Kaushik Khona	ABQPK8317D	Key Management Personnel	Remuneration		-				146.13	0	0	
15	Ceinsys Tech Limited	AACCA3193K	Mr. Prakash Yadav	ABBPY7759E	Key Management Personnel	Remuneration		-				37.5	0	0	
16	Ceinsys Tech Limited	AACCA3193K	Mr. Sagar Meghe	ABYPM6079Q	Non-Executive Director Non-Independent Director	Any other transaction	Sitting Fees	-				8	0	0	
17	Ceinsys Tech Limited	AACCA3193K	Yeshwantrao Chavan College of Engineering	AAATN0914E	Significant influence	Purchase of goods or services		-				0.25	0	0	
18	Ceinsys Tech Limited	AACCA3193K	SMG Realties Pvt Ltd	AAGCS4275G	Significant influence	Any other transaction	Debit note raised	-				0.7	0.7	0	
19	Ceinsys Tech Limited	AACCA3193K	ADCC Infocom Private Limited	AAICA7011N	Subsidiary Company	Any other transaction	Refund of Interest	-				2.64	2.97	5.61	
20	Ceinsys Tech Limited	AACCA3193K	Vrishali Kamat	AXPPK0352D	Relative of KMP	Any other transaction	Security Deposit	-				0	0.23	0.23	
21	Ceinsys Tech Limited	AACCA3193K	Rohan Singh	CIOPS2949N	Relative of KMP	Remuneration		-				5.38	0	0	
22	Ceinsys Tech Limited*	AACCA3193K	Technology Associates INC.	AAGCT0670C	Subsidiary Company	Sale of goods or services		-				331.69	101.38	383.40	
23	Ceinsys Tech Limited*	AACCA3193K	Allygrow Technologies GmbH	ZZZZZ9999Z	Subsidiary Company	Sale of goods or services		-				389.05	143.54	130.87	
24	Ceinsys Tech Limited*	AACCA3193K	Allygrow Technologies BV	ZZZZZ9999Z	Subsidiary Company	Interest received		-				0.29	27.26	27.2	



Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Chaturvedi & Shah LLP	Yes	30-06-2026

<b>Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)</b>	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	20-11-2024
Amount Raised	23506
Report filed for Quarter ended	31-03-2025
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	Care Ratings Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	Not Applicable
Comments of the Audit Committee after review	No Comments
Comments of the auditors, if any	No Comments

Sr.	Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation for the quarter according to applicable object	Remarks if any
1	i.Expansion of existing business operations and setting up a delivery center of Company in India. ii.Strategic business acquisitions/ investments outside India. iii.Working Capital Requirements.	Nil	24340	23506	1.15	0	<p>Note-1: The Board of Directors and Shareholders of the Company had approved the preferential issue of 12,50,658 Equity Shares to 4 proposed allottees (non-promoters) at Rs. 559.90 per equity share and 30,96,515 Share Warrants to 4 proposed allottees at Rs. 559.90 per Share Warrant, aggregate to Rs. 243.40 Cr but one of the proposed allottee of 1,48,909 Equity Shares has not availed the offer of preferential issue worth of Rs. 8.34 Cr and accordingly revised preferential issue size is Rs. 235.06 Cr. made up of 11,01,749 equity shares and 30,96,515 Share warrants.</p> <p>Note-2: "Purposes and objects of the offer" clause in the Private Placement Offer cum Application Letter ("Offer Letter") doesn't provide the Original Cost to be utilized under each item head, however Total Estimated Amount to be utilized for each of the objects was approved by the Board of Directors in their meeting dated March 30, 2024 and Shareholders of the Company in the EGM dated April 29, 2024, but since one of the proposed allottees of Equity Shares has not availed the offer and issue size revised to Rs. 235.06 Crores, accordingly there are revision in cost i.e. revision in Estimated Amount to be utilised to maximum of Rs. 235.06 Crores.</p> <p>Note-3: As per Offer Document, the Company received the full amount of preferential issue of 11,01,749 Equity Shares i.e. of Rs. 61.69 Crores and 25% of preferential issue of 30,96,515 Convertible Shares Warrants in 1st tranche i.e. of Rs. 43.34 Crores, so total amount raised till March 31, 2025, is Rs. 105.0304 Crores out of which 0.0115 Crores has been utilized for Working Capital Purpose and balance amount of Rs. 105.0189 Crores are Unutilized.</p> <p>Note-4: As on March 31, 2025, the unutilized amount of Rs. 105.00 Crores has been invested in term deposits and balance of Rs. 0.0189 Crores is lying in a separate bank account. The Company has received the excess amount of Rs. 0.22 Crores from the proposed allottees, which was refunded on October 17, 2024 and accordingly the balance as on March 31, 2025, of above mentioned SBI Bank account is Rs. 0.0189 Crores.</p>

<b>Signatory Details</b>	
Name of signatory	Samir Sabharwal
Designation of person	Chief Financial Officer
Place	Nagpur
Date	30-04-2025

Format for Disclosing Outstanding Default on Loans and Debt Securities			
Sr. No.	Particulars	Amount	Remarks
1.	Loans / revolving facilities like cash credit from banks / financial institutions		
A	Total amount outstanding as on date	3660.92	
B	Of the total amount outstanding, amount of default as on date	0	
2.	Unlisted debt securities i.e. NCDs and NCRPS		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0	

